• Biomolecules & Therapeutics
• /
• 제16권1호
• /
• pp.54-60
• /
• 2008

Dyslipidemia is the multiple lipid metabolic disorders which is one of the high risk factors for the atherosclerotic diseases. It increases the morbidity and mortality and therefore, must be treated with antilipidemic agents. HMG-Co A reductase inhibitors (statins), one of many antidyslipidemic agents, have shown to be significant improvement from the various cholesterol levels. Especially, data from many comparative trials suggest that rosuvastatin is more effective than atorvastatin among many other statins. The aims of this study were to evaluate the efficacy and safety between rosuvastatin and atorvastatin in the treatment of Korean patients with dyslipidemia. Currently the Korean Society of Lipidology and Atherosclerosis based on the Korean health screening data suggests that Korean patients with dyslipidemia should be treated by the target cholesterol levels according to the Adult Treatment Panel III guidelines of the US National Cholesterol Education Program (NCEP-ATP III). We reviewed retrospectively all medical histories of the total 392 dyslipidemic patients with atorvastatin or rosuvastatin from June 1st, 2004 to August 31st, 2006 in Chungbuk National University Medical Center. Patients were classified as total 4 groups by the NCEP-ATP III Guidelines. The numbers of enrolled patients were each 5 mg atorvastatin (n=34), 10 mg atorvastatin (n=148), 5 mg rosuvastatin (n=94) and 10 mg rosuvastatin (n=82). In comparison between groups, rosuvastatin groups in the lowering LDL-C had better efficacies, and the results were each 22% (5 mg atorvastatin), 33.3% (10 mg atorvastatin), 35% (5 mg rosuvastatin) and 41.3% (10 mg rosuvastatin) with the dose relationship (P=0.000). Rosuvastatin groups also have shown to be more significantly reducing Total Cholesterol levels compared to atorvastatin groups with the no dose relationship (P=0.000). In the lowering of non-HDL cholesteroles, rosuvastatin groups showed significantly better efficacies than atorvastatin with the dose-relationship (P=0.000). Each medication groups did not demonstrate the differences in the changing of HDL cholesterol and triglyceride levels (P=0.096, 0.309, respectively). In conclusion, rosuvastatin was better efficacious than atrovastatin in reducing LDL-C Total Chol, and Tg. Therefore, rosuvastatin is a good antilipidemic agents for Korean patients with dyslipidemia and it can use to minimize the morbidity and mortality related to the cardiovascular diseases in Korean.

• 디지털융복합연구
• /
• 제14권1호
• /
• pp.327-338
• /
• 2016

본 연구의 목적은 이상지질혈증군과 정상군을 구분하여 한국인 남녀에서 이상지질혈증 발생과 건강생활 실천의 영향을 파악하기 위함이다. 연구대상은 제5기(2010년~2012년) 국민건강영양조사에서 공개된 제3차년도(2012년) 자료 중에서 건강 설문 자료를 분석대상으로 하였으며, 대상자는 우리나라의 질병 발생 양상 및 의료 환경 등을 고려해 만든 한국지질 동맥경화학회(KSLA: Korean Society of Lipidology and Atherosclerosis, 2009)의 이상지질혈증 치료지침을 적용하여 만 19세 이상 이상지질혈증군 2,092명(남자 1,042명, 여자 1,050명)과 정상군 1,944명(남자 740명, 여자 1,204명)인 4,036명이었다. 본 연구는 SPSS 18.0 프로그램을 이용하여 서술적 통계의 t-test와 ${\chi}^2-test$, 로지스틱 회귀분석을 사용하였다. 본 연구의 결과를 토대로 이상지질혈증 관련 건강생활 실천 프로그램은 혈청 지질 농도에 차이를 보이고 있는 한국인 남녀의 특성을 고려하여 적용하여야 하며, 이를 위해 지속적인 연구 및 건강생활 실천의 효과를 적용한 체계적인 국가 차원의 맞춤교육이 필요하다고 사료된다.

• Journal of Nutrition and Health
• /
• 제51권1호
• /
• pp.40-49
• /
• 2018

본 연구는 SELEN 코호트 연구의 기반조사 자료를 활용하였으며, 성인 남녀의 발톱 크롬 수준에 독립적으로 영향을 미치는 결정요인을 파악하고, 크롬 수준과 이상지질혈증과의 관련성을 규명하고자 하였다. 그 결과, 면류, 채소류, 과일류가 발톱 크롬 수준에 독립적으로 영향을 주었으며, 교란인자를 보정한 후 크롬 수준과 주요 이상지질혈증간의 유의적인 연관성을 보이지 않았다. 그러나 발톱 크롬 농도에 독립적으로 영향을 미치는 요인을 찾아내어 제시하게 된 바, 한국인을 대상으로 한 최초의 크롬 관련 영양 역학연구의 결과로서 그 의의가 크다. 또한 국내 연구가 부족한 상황에서 본 연구 결과는 크롬의 한국인 영양 섭취 기준 개정 시 기초자료로 활용될 수 있을 것으로 기대한다. 향후 크롬 섭취 및 체내 크롬 농도와 이상지질혈증과의 명확한 관련성을 규명하기 위하여 한국인 크롬 식이 데이터베이스를 구축하고, 대규모 코호트 연구와 임상시험연구가 진행되어야 할 것으로 사료된다.

• 대한임상검사과학회지
• /
• 제54권2호
• /
• pp.95-102
• /
• 2022

Lp(a)와 이상지질혈증의 관계가 명확하지 않아, 본 연구는 60세 이상 노인 환자를 대상으로 Lp(a)와 이상지질혈증의 관계를 조사하고자 하였다. 2014년 1월 1일부터 2020년 12월 31일까지 7년간 한 종합병원을 내원한 60세 이상 노인 중 나이, 성별, BMI, Lp(a), LDL-C, TG, HDL-C, hs-CRP, HbA1c, 지질강하제 복용 여부, 이상지질혈증 의사진단여부 등의 기록이 있는 2,580명을 최종 분석대상자로 선정하였다. Lp(a)와의 상관성은 hs-CRP (r=0.138), LDL-C (r=0.097), HDL-C (r=-0.089), TG (r=-0.073), 나이(r=0.072) 등이 유의하였으며, BMI, HbA1c는 유의하지 않았다. 변수들을 보정한 Lp(a)와 LDL-C의 편상관관계는 남성그룹에서만 유의하였다(r=0.158, P<0.001). 본 연구에서 이상지질혈증에 대한 Lp(a)의 4사분위의 교차비(교차비=1.376, 95% 신뢰구간=1.038~1.822)가 유의하게 나타남으로써 지질강하제 복용으로도 1차 표적인 LDL-C 수준을 낮추지 못했을 때, 2차적으로 고려해봐야 할 여러 요소 중 Lp(a)도 포함되어야 한다고 판단된다. 성별, 연령, 지질강하제 복용 여부 등에 따른 다양한 지질인자들에 대한 연구들이 필요하다고 사료된다.

• Preventive Nutrition and Food Science
• /
• 제14권1호
• /
• pp.1-7
• /
• 2009

Control of hyperglycemia and dyslipidemia is strongly correlated with decreased risk for cardiovascular disease, the most common and fatal diabetic complication. The purpose of this study is to determine the effects of garlic and aged black garlic on glycemic control and blood lipid profile in animal model of type 2 diabetes. Three week-old db/db mice (C57BL/Ks, n=21) were fed AIN-93G semipurified diet or diet containing 5% freeze-dried garlic or aged black garlic for 7 weeks after 1 week of adaptation. Fasting serum glucose, insulin, triglyceride, total cholesterol, and HDL-cholesterol and blood glycated hemoglobin were measured. Body weight and food intake of garlic and aged black garlic group were not significantly different from those of the control group. Fasting serum glucose and blood glycated hemoglobin levels were significantly decreased and insulin level was significantly increased in garlic group compared with control group (p<0.05). Consumption of aged black garlic significantly decreased homeostasis model assessment for insulin resistance (HOMA-IR) and tended to decrease serum glucose. Garlic consumption significantly decreased total cholesterol, while aged black garlic significantly reduced serum total cholesterol and triglyceride and increased HDL-cholesterol levels. These results suggest that garlic exerts hypoglycemic and hypocholesterolemic effect and aged black garlic improved insulin sensitivity and dyslipidemia in db/db mice.

• 대한한의학회지
• /
• 제41권2호
• /
• pp.43-57
• /
• 2020

Objectives: The purpose of this study was to investigate the effect of Phellinus linteus cheonghyeol plus (PLCP) on antioxidant and inhibition of inflammatory factor expression associated with dyslipidemia in HUVEC. Methods: The scavenging activity of DPPH and ABTS radical of PLCP was measured in HUVEC. The expression levels of NF-κB, p-IκBα, ERK, JNK, and p38 proteins were measured after treating with TNF-α in HUVEC. The expression levels of MCP-1, ICAM-1, and VCAM-1 mRNA and biomarkers were measured after treatment with TNF-α in HUVEC Results: 1. PLCP increases DPPH and ABTS radical scavenging activity in a concentration dependent manner. 2. PLCP significantly decreased the concentration of NF-κB, p-IκBα, ERK, JNK protein compared to the control at concentrations of 100 ㎍/㎖ or more, and significantly decreased concentration of p38 protein at all concentrations. 3. PLCP significantly decreased MCP-1 mRNA expression levels at 100㎍/㎖ or more compared to the control. ICAM-1 and VCAM-1 mRNA expression levels were significantly reduced at all concentrations compared to the control. MCP-1, ICAM-1 protein expression levels were significantly reduced compared to the control at concentrations of 100 ㎍/㎖ or more, and VCAM-1 protein expression levels were reduced at all concentrations. Conclusions: These results suggest that PLCP has an antioxidant effect, and it has been experimentally confirmed that it can prevent or inhibit inflammatory diseases caused by dyslipidemia due to its inhibitory effect on inflammation-related factors in HUVEC.

• 혜화의학회지
• /
• 제25권1호
• /
• pp.133-144
• /
• 2016

Objectives : This study was aimed to investigate the effect of ACLL extract (Artemisia capillaris Thunb, Curcuma longa L, Lycium chinense, Ligustrum lucidum Aiton complex extract) in a dyslipidemia animal model induced by a high-fat diet. Methods : ACLL extracts was administered at 200 mg/kg, and 400 mg/kg to Apoe mice, where arthritis was induced by high cholesterol diet. After mice were treated with GO for 4 weeks, we measured AST, ALT, BUN and lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride), atherogenic index(AI) and cardiac risk factor(CRF). Results : Serum AST, ALT, creatinine, BUN levels were not changed by ACLL extract do not show any toxic effects. Also, ACLL extract groups were found to have atherogenic Index and cardiac risk factor as well as lipid metabolism improvement (total cholesterol, LDL cholesterol and triglyceride decrease). Conclusions : We suggest that ACLL extract may have the control effects of Dyslipidemia by improving lipid metabolism.

• 대한한방내과학회지
• /
• 제40권6호
• /
• pp.1026-1034
• /
• 2019

Objective: This study was conducted to investigate the lipid-lowering effect and safety of Daeshiho-tang in patients with uncontrolled lipid levels by statins. Methods: We investigated patients who had an abnormal lipid profile even when taking statins and who were administered Daeshiho-tang at Kyung-Hee University Korean Medical Hospital for at least one day between January 2008 and December 2018. Their basal characteristics and examinations were reviewed retrospectively with respect to lipid profile, AST, ALT, GGT, BUN, and creatinine. The lipid profile was composed of total cholesterol, triglyceride, LDL-cholesterol, and HDL-cholesterol. Subgroup analysis was performed on each component of dyslipidemia. Results: Among 20 participants, there were 10 males and 10 females. The mean BMI was 23.52. Eighty five percent of the participants were diagnosed as having cerebral infarction. After the administration of Daeshiho-tang, total cholesterol and LDL cholesterol were significantly reduced, to 41.3 mg/dl and 33.95 mg/dl, respectively. In subgroup analyses, total cholesterol and LDL cholesterol were significantly decreased, to 63 mg/dl and 54.6 mg/dl, respectively. Liver and kidney function showed no significant difference after taking Daeshiho-tang. Conclusions: Daeshiho-tang as a decoction or powder had significant lipid-lowering effects on total cholesterol and LDL cholesterol in patients with dyslipidemia. The lipid-lowering effect on total and LDL cholesterol increased in patients with hypercholesterolemia and hyper-LDL-cholesterolemia, respectively. Based on the minimal changes in the liver and kidney function test, Daeshiho-tang would be safe enough to be used in clinics.

• 약학회지
• /
• 제45권5호
• /
• pp.468-475
• /
• 2001

Fenofibrate is a fibric acid derivative that is a strong reducer of triglyceride. Micronozed formulation of fenofibrate has improved bioavailability compared to non-micrornized formulation. This study performed a retrospective comparison of micrornized and non-micrornized fenofibrate (28 in micronized and 51 in non-micronized group) by comparing the means of changes in total triglyceride, total cholesterol, HDL-cholesterol and TC/HDL ratio in type 2 diabetics with dyslipidemia The result skewed that after 12 weeks of treatment both drugs produced a significant reduction in total triglyceride levels (62% with micronized, 37% with non-micronized). The mean decrease observed for total triglyceride levels were significantly lower for micronized fenofibrate (p<0.001). Both drugs showed a significant reduction for total cholesterol levels (-22% with micronized, -14% with non-micronized fenofibrate). The mean decrease observed for total cholesterol was not significantly different between the two drugs (p>0.05). HDL-cholesterol levels increased by 24% and 15%) with micronized and non-micronized, respectively and the differences from the baseline were statistically significant for both drugs (p<0.05). The mean change of HDL-cholesterol was not significantly different between the two drugs. There was a statistically significant reduction in TC/HBL-cholesterol ratio from baseline for both drugs (7.1 to 4.8 with micronized and 5.1 to 4.5 with non-micronized), and the reduction of TC/HDL-cholesterol ratio tended to be significantly greater with micronized fenofibrate (p<0.05). This study shows that short-term treatment with micronized fenofibrate is more effective than non-micronized fenosbrate in type 2 diabetes patients with dyslipidemia.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제20권4호
• /
• pp.263-267
• /
• 2017

Patients with lysosomal acid lipase (LAL) deficiency and glycogen storage disease (GSD) demonstrated hepatomegaly and dyslipidemia. In our case, a 6-year-old boy presented with hepatosplenomegaly. At 3 years of age, GSD had been diagnosed by liver biopsy at another hospital. He showed elevated serum liver enzymes and dyslipidemia. Liver biopsy revealed diffuse microvesicular fatty changes in hepatocytes, septal fibrosis and foamy macrophages. Ultrastructural examination demonstrated numerous lysosomes that contained lipid material and intracytoplasmic cholesterol clefts. A dried blood spot test revealed markedly decreased activity of LAL. LIPA gene sequencing identified the presence of a novel homozygous mutation (p.Thr177Ile). The patient's elevated liver enzymes and dyslipidemia improved with enzyme replacement therapy. This is the first report of a Korean child with LAL deficiency, and our findings suggest that this condition should be considered in the differential diagnosis of children with hepatosplenomegaly and dyslipidemia.